Second Patient Dies in Carmat's Artificial Heart Trial
May 5 (Reuters) - Trading in Carmat shares was suspended on Tuesday after the company's second artificial heart patient died on Saturday, nine months after receiving the transplant.
A source close to the matter said the Euronext stock exchange granted the suspension to give medical teams time to pinpoint the reasons for the death, and that a statement could be issued after the market close.
An abnormality was discovered with the device after the 69-year-old man was admitted to hospital on Friday suffering circulatory failure, and he was placed in intensive care, Carmat said on Monday.
Help employers find you! Check out all the jobs and post your resume.
A source close to the matter said the Euronext stock exchange granted the suspension to give medical teams time to pinpoint the reasons for the death, and that a statement could be issued after the market close.
An abnormality was discovered with the device after the 69-year-old man was admitted to hospital on Friday suffering circulatory failure, and he was placed in intensive care, Carmat said on Monday.
Help employers find you! Check out all the jobs and post your resume.